QIFT and PIFT from JBNI

JBNI has been leading the world in cancer prevention research for over a decade. JBNI's presentations on "Cancer Forecasting Proteomics" have been most highly regarded in every international conferences sponsored by NIH (National Institute of Health), NCI ((National Cancer Institute), AACR ( American Association for Cancer Research) and EORTC(European Organization for Research and Treatment of Cancer). JBNI's philosophy and technology in prevention has already gone beyond the wildest expectation of modern world. PIFT (Proteomic Illness Forecasting Test) will "forecast" each individual's cancer and common illnesses years before their earliest stage, which gives everyone many years to prevent such conditions safely with natural modalities. QIFT (Quarterly Illness Forecasting Test) will eliminate the guess work on efficacy of your natural modalities. You will be able to monitor your healthy future precisely and adjust your life style to improve and extend your life. JBNI believes that Homo Sapiens' learning through physical struggle should end, and that new humanity, Homo Sanctus, will advance through polishing of mind.

also check www.aacr.org / www.eortc.org / www.nih.gov / www.cancer.gov / www.ctrc.org / www.idd.org

Renal Cell Carcinoma

Renal cell carcinoma (RCC) is often undetected until it is in an advanced stage. Currently there are no reliable blood biomarkers to monitor the presence of the disease and/or response to therapies. Mass spectrometry (MS)-based proteomics provides tools for sensitive and high-throughput protein screening of biological samples and biomarker discovery.

SAA, an inflammatory acute phase protein, has been viewed as a biomarker of host response in many human cancers. The recently reported presence of SAA in tumor tissue suggests alternative function of the protein. Sudden disappearance of SAA versus persistent upregulation of multiple inflammatory proteins in post-nephrectomy RCC sera supports this notion. Selective proteome isolation by targeted MS is a promising analytical tool with potential clinical applications.

Historical Breakthrough in Treatment of Asthma

JBNI has received an FDA Investigational New Drug Number for our novel natural drug for chronic and debilitating Asthma. This is the first in a line of comprehensive natural, efficacious therapies for chronic medical conditions. Results of our research conducted in conjunction with CTRC Institute for Drug Development, San Antonio, TX, were presented in an abstract entitled "Efficacy, short-term safety, and serum biomarkers in a clinical trial of IND#70190" at the San Antonio Cancer Institute by Dr. Elzbieta Izbicka, chief investigator.
http://jbni.us/images/news1.jpg

A Proteomics Victory Over Cancer

04/14/07: Latest RCC Abstract

06/14/06: Our latest abstract

July 2005 our research in the battle against cancer won recognition in the scientific and pharmaceutical community to the extent that we have been presented on the cover of the July-August issue of " Cancer Genomics & Proteomics" , a journal published by the International Institute of Anticancer Research.

Novel natural products LP-01 and LP-02 developed by JBNI, were presented in cooperation with CTRC The Institute for Drug Development, San Antonio, TX at AACR-NCI-EORTC 2004: September 28-October 1, Geneva, Switzerland The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications was held in Geneva, Switzerland this past September. Our abstract on Serum Proteomic Biomarkers of a Natural Product in a Prospective Randomized Placebo-Controlled Clinical Trial in patients at risk for lung cancer was presented to the acclaim of the attendees.

In November of 2003, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Discovery Biology, and Clinical Applications held in Boston, Massachusetts, an abstract entitled "Serum Biomarkers of Natural Product Therapy in Human Lung Cancer Xenograft Models" was presented, demonstrating the efficacy of our novel entities (LP-01 and LP-02) in high-risk lung cancer patients.

read our report on Novel serum biomarkers for renal cell carcinoma